These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24837410)

  • 1. Bactericidal effect of sulbactam against Acinetobacter baumannii ATCC 19606 studied by 2D-DIGE and mass spectrometry.
    Lin CH; Su SC; Ho KH; Hsu YW; Lee KR
    Int J Antimicrob Agents; 2014 Jul; 44(1):38-46. PubMed ID: 24837410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii.
    McLeod SM; Shapiro AB; Moussa SH; Johnstone M; McLaughlin RE; de Jonge BLM; Miller AA
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities of various beta-lactams and beta-lactam/beta-lactamase inhibitor combinations against Acinetobacter baumannii and Acinetobacter DNA group 3 strains.
    Brauers J; Frank U; Kresken M; Rodloff AC; Seifert H
    Clin Microbiol Infect; 2005 Jan; 11(1):24-30. PubMed ID: 15649300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular docking and simulation of the interaction of sulbactam with Acinetobacter baumannii BaeSR and AdeSR.
    Ho KH; Su SC; Lee KR
    Biochem Biophys Res Commun; 2021 Nov; 580():81-86. PubMed ID: 34627000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models.
    Yokoyama Y; Matsumoto K; Ikawa K; Watanabe E; Shigemi A; Umezaki Y; Nakamura K; Ueno K; Morikawa N; Takeda Y
    Int J Antimicrob Agents; 2014 Jun; 43(6):547-52. PubMed ID: 24796218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.
    Penwell WF; Shapiro AB; Giacobbe RA; Gu RF; Gao N; Thresher J; McLaughlin RE; Huband MD; DeJonge BL; Ehmann DE; Miller AA
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1680-9. PubMed ID: 25561334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Difference in imipenem, meropenem, sulbactam, and colistin nonsusceptibility trends among three phenotypically undifferentiated Acinetobacter baumannii complex in a medical center in Taiwan, 1997-2007.
    Liang-Yu C; Kuo SC; Liu CY; Luo BS; Huang LJ; Lee YT; Chen CP; Chen TL; Fung CP
    J Microbiol Immunol Infect; 2011 Oct; 44(5):358-63. PubMed ID: 21524973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
    Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
    J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of resistance to ciprofloxacin, ampicillin/sulbactam and imipenem in Acinetobacter baumannii clinical isolates in Taiwan.
    Chiu CH; Lee HY; Tseng LY; Chen CL; Chia JH; Su LH; Liu SY
    Int J Antimicrob Agents; 2010 Apr; 35(4):382-6. PubMed ID: 20138741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.
    Song JY; Kee SY; Hwang IS; Seo YB; Jeong HW; Kim WJ; Cheong HJ
    J Antimicrob Chemother; 2007 Aug; 60(2):317-22. PubMed ID: 17540672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro resistance development in Acinetobacter baumannii to sulbactam and cefoperazone].
    Wieczorek P; Sacha P; Ojdana D; Milewski R; Jurczak A; Kaczyńska K; Tryniszewska E
    Med Dosw Mikrobiol; 2012; 64(1):55-62. PubMed ID: 22808730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.
    Housman ST; Hagihara M; Nicolau DP; Kuti JL
    J Antimicrob Chemother; 2013 Oct; 68(10):2296-304. PubMed ID: 23710070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of putative non-host essential genes and novel drug targets against Acinetobacter baumannii by in silico comparative genome analysis.
    Uddin R; Masood F; Azam SS; Wadood A
    Microb Pathog; 2019 Mar; 128():28-35. PubMed ID: 30550846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effects of sulbactam in multi-drug-resistant Acinetobacter baumannii.
    Temocin F; Erdinc FS; Tulek N; Demirelli M; Ertem G; Kinikli S; Koksal E
    Braz J Microbiol; 2015; 46(4):1119-24. PubMed ID: 26691470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergic in-vitro activity of imipenem and sulbactam against Acinetobacter baumannii.
    Choi JY; Park YS; Cho CH; Park YS; Shin SY; Song YG; Yong D; Lee K; Kim JM
    Clin Microbiol Infect; 2004 Dec; 10(12):1098-101. PubMed ID: 15606639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular characterization of beta-lactamase-associated resistance in Acinetobacter baumannii strains isolated from clinical samples].
    Keskin H; Tekeli A; Dolapci İ; Öcal D
    Mikrobiyol Bul; 2014 Jul; 48(3):365-76. PubMed ID: 25052103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective evaluation of synergistic effect of sulbactam and tazobactam combination with meropenem or colistin against multidrug resistant Acinetobacter baumannii.
    Marie MA; Krishnappa LG; Alzahrani AJ; Mubaraki MA; Alyousef AA
    Bosn J Basic Med Sci; 2015 Oct; 15(4):24-9. PubMed ID: 26614848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases.
    Tripodi MF; Durante-Mangoni E; Fortunato R; Utili R; Zarrilli R
    Int J Antimicrob Agents; 2007 Dec; 30(6):537-40. PubMed ID: 17851050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of sulbactam and its combination with imipenem, colistin and tigecycline in an experimental model of carbapenem-resistant Acinetobacter baumannii sepsis.
    Dinc G; Demiraslan H; Elmali F; Ahmed SS; Metan G; Alp E; Doganay M
    Chemotherapy; 2013; 59(5):325-9. PubMed ID: 24525528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of colistin plus sulbactam against extensive-drug-resistant Acinetobacter baumannii by checkerboard method.
    Thamlikitkul V; Tiengrim S
    J Med Assoc Thai; 2014 Mar; 97 Suppl 3():S1-6. PubMed ID: 24772574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.